Reuters: Regulatory News: XenoPort to drop multiple sclerosis drug after trial failure

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

XenoPort to drop multiple sclerosis drug after trial failure May 20th 2013, 10:42 Mon May 20, 2013 6:42am EDT May 20 (Reuters) - XenoPort Inc said it will stop developing its experimental multiple sclerosis treatment after data from a late-stage trial showed the drug did not improve patients' condition significantly compared with a placebo. The company said it will shut down all activities related to the drug, arbaclofen placarbil, and planned to provide an update on the impact of the expected savings.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions